Epigenetic Targets for Oligonucleotide Therapies of Pulmonary Arterial Hypertension.

ABSTRACT: Arterial wall remodeling underlies increased pulmonary vascular resistance and right heart failure in pulmonary arterial hypertension (PAH). None of the established vasodilator drug therapies for PAH prevents or reverse established arterial wall thickening, stiffening, and hypercontractility. Therefore, new approaches are needed to achieve long-acting prevention and reversal of occlusive pulmonary vascular remodeling. Several promising new drug classes are emerging from a better understanding of pulmonary vascular gene expression programs. In this review, potential epigenetic targets for small molecules and oligonucleotides will be described. Most are in preclinical studies aimed at modifying the growth of vascular wall cells in vitro or normalizing vascular remodeling in PAH animal models

SUBMITTER: Gerthoffer W 

PROVIDER: S-EPMC7731052 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature